Mismatch repair status in sporadic colorectal cancer: Immunohistochemistry and microsatellite instability analyses

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 12, 2011, Pages 1733-1739

  Yoon, Yong Sik ^a   Yu, Chang Sik ^a   Kim, Tae Won ^a   Kim, Jong Hoon ^a   Jang, Se Jin ^a   Cho, Dong Hyung ^a,b   Roh, Seon Ae ^a   Kim, Jin Cheon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Colorectal adenocarcinoma; Immunohistochemistry; Microsatellite instability; Mismatch repair; Prognosis

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

EID: 81855166256     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06784.x     Document Type: Article

References (38)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005; 365: 153-65.
2. Vogelstein B, Fearon ER, Hamilton SR etal. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319: 525-32.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
4. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-19.
5. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol. 2002; 3: 83-8.
6. Gryfe R, Kim H, Hsieh ET etal. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000; 342: 69-77.
7. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005; 23: 609-18.
8. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J. Mol. Diagn. 2008; 10: 301-7.
9. Shia J, Ellis NA, Klimstra DS. The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch. 2004; 445: 431-41.
10. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J. Mol. Diagn. 2008; 10: 293-300.
11. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol. 2006; 24: 2359-67.
12. Lindor NM, Burgart LJ, Leontovich O etal. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 2002; 20: 1043-8.
13. Rigau V, Sebbagh N, Olschwang S etal. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 (correction of hMLH6) immunostaining. Arch. Pathol. Lab. Med. 2003; 127: 694-700.
14. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur. J. Cancer 2009; 45: 1935-49.
15. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res. 2009; 29: 1615-20.
16. Kim GP, Colangelo LH, Wieand HS etal. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 2007; 25: 767-72.
17. Benson AB, Schrag D, Somerfield MR etal. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 2004; 22: 3408-19.
18. Gill S, Loprinzi CL, Sargent DJ etal. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 2004; 22: 1797-806.
19. Boland CR, Thibodeau SN, Hamilton SR etal. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-57.
20. Kim JC, Cho YK, Roh SA etal. Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. Cancer Sci. 2008; 99: 1348-54.
21. Kim JC, Lee KH, Ka IH etal. Characterization of mutator phenotype in familial colorectal cancer patients not fulfilling amsterdam criteria. Clin. Cancer Res. 2004; 10: 6159-68.
22. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am. J. Surg. Pathol. 2000; 24: 1016-19.
23. Ward R, Meagher A, Tomlinson I etal. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001; 48: 821-9.
24. Poynter JN, Siegmund KD, Weisenberger DJ etal. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 3208-15.
25. Barrow E, McMahon R, Evans DG, Levine E, Hill J. Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. Br. J. Surg. 2008; 95: 868-75.
26. Suh JH, Lim SD, Kim JC, Hong SH, Kang GH. Comparison of clinicopathologic characteristics and genetic alterations between microsatellite instability-positive and microsatellite instability-negative sporadic colorectal carcinomas in patients younger than 40years old. Dis. Colon. Rectum. 2002; 45: 219-28.
27. Zhang H, Richards B, Wilson T etal. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res. 1999; 59: 3021-7.
28. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6: 322-7.
29. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 1999; 36: 801-18.
30. Benatti P, Gafa R, Barana D etal. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 2005; 11: 8332-40.
31. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 2009; 45: 1890-6.
32. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-50.
33. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-8.
34. Carethers JM, Chauhan DP, Fink D etal. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-31.
35. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001; 61: 5193-201.
36. Carethers JM, Smith EJ, Behling CA etal. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
37. Jover R, Zapater P, Castells A etal. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 2009; 45: 365-73.
38. Ribic CM, Sargent DJ, Moore MJ etal. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003; 349: 247-57.